Home » Newsletters » BioWorld Science

BioWorld Science

June 16, 2008

View Archived Issues

Phase II results with CPX-1 liposome injection reported

Improved insulin sensitivity and cholesterol-lowering activity of INCB-13739 in type 2 diabetes

SGLT2-specific antisense oligonucleotide shows antidiabetic activity in vivo

Novel glucokinase activator normalizes blood glucose in mild and severe diabetes models

Axelar receives financing for a phase I/II clinical trial for AXL-1717 in cancer

Rigel commences two phase IIb trials of R-788 in rheumatoid arthritis

Good tolerability and preliminary efficacy of baminercept in rheumatoid arthritis

Molecular Insight initiates phase I Trofex trial in metastatic prostate cancer

BioLineRx begins phase IIb BL-1020 trial in schizophrenia

GlaxoSmithKline receives E.U. marketing authorization for Tyverb

Novartis starts clinical trials for influenza vaccine adjuvanted with Intercell's IC31

Novartis launches oral iron-chelating agent Exjade for chronic iron overload in Japan

Positive phase I/II IDX-899 data confirm potent antiviral activity in HIV

Recent patents report novel analgesic agents

Calando and City of Hope to initiate phase II clinical trial of IT-101 in lymphoma

Novel treatments for disorders of impaired metabolism described in recent patent literature

ChemoCentryx completes enrollment in phase II/III PROTECT-1 clinical trial of Traficet-EN

Repligen to initiate phase IIb clinical trial of RG-2417 in bipolar disorder

Cytomedix to enter antiinflammatory peptide CT-112 into clinical development

Agents for Alzheimer's disease and other neurological disorders disclosed in recent patents

Axxonis submits MAA to EMEA for Nenad transdermal patch and subcutaneous infusion

Results from three phase I clinical trials of Cytokinetics' CK-1827452 reported

Ranbaxy to become subsidiary of Daiichi Sankyo

FDA approves Requip XL for Parkinson's disease

Chemokine reports final results of CTCE-9908 phase I/II trial in cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...